文献速递呼吸道感染间质性肺疾病

囊性纤维化肺上皮干细胞变异体的炎症活性不能被CFTR调节剂缓解

Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

研究从接受肺移植的终末期囊性纤维化(CF)患者肺组织分离干细胞克隆,发现除正常肺干细胞外存在五种主要变异体,其中三种在基因表达和异种移植中均驱动中性粒细胞炎症。基因补全或药物调节CFTR活性均不能消除这三种变异体的促炎功能,提示其可能解释CF患者在接受CFTR调节剂治疗时肺部炎症持续存在。

要点

  • 终末期CF肺存在五种干细胞变异体,其中三种具有促炎性。
  • 三种促炎变异体驱动中性粒细胞炎症,CFTR调节剂不能缓解。
  • 晚期CF患者肺部炎症持续可能与这些促炎干细胞变异体有关。

核心结论

  • CF肺中出现的三种促炎干细胞变异体可能贡献于晚期CF患者接受CFTR调节剂治疗时肺部炎症的持续存在。

研究设计与样本

  • 研究应用干细胞克隆技术处理接受肺移植的终末期CF患者肺组织(三例CFTR F508D纯合,一例CFTR F508D/L1254X;FEV1 14-30%),并通过单细胞RNA测序、RNA测序和异种移植评估炎症、纤维化和黏蛋白分泌。

主要发现

  • 终末期CF肺显示干细胞异质性,除正常肺干细胞外有五种主要变异体,其中三种在基因表达和异种移植中驱动中性粒细胞炎症。
  • 这三种促炎变异体的促炎功能在基因补全或药物恢复CFTR活性后未被缓解。

临床怎么用

  • 对于接受CFTR调节剂治疗的晚期CF患者,肺部炎症可能持续存在,需关注促炎干细胞变异体作为潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: CFTR (cystic fibrosis transmembrane conductance regulator) modulator drugs restore function to mutant channels in patients with cystic fibrosis (CF) and lead to improvements in body mass index and lung function. Although it is anticipated that early childhood treatment with CFTR modulators will significantly delay or even prevent the onset of advanced lung disease, lung neutrophils and inflammatory cytokines remain high in patients with CF with established lung disease despite modulator therapy, underscoring the need to identify and ultimately target the sources of this inflammation in CF lungs. Objectives: To determine whether CF lungs, like chronic obstructive pulmonary disease (COPD) lungs, harbor potentially pathogenic stem cell "variants" distinct from the normal p63/Krt5 lung stem cells devoted to alveolar fates, to identify specific variants that might contribute to the inflammatory state of CF lungs, and to assess the impact of CFTR genetic complementation or CFTR modulators on the inflammatory variants identified herein. Methods: Stem cell cloning technology developed to resolve pathogenic stem cell heterogeneity in COPD and idiopathic pulmonary fibrosis lungs was applied to end-stage lungs of patients with CF (three homozygous CFTR:F508D, one CFTR F508D/L1254X; FEV1, 14-30%) undergoing therapeutic lung transplantation. Single-cell-derived clones corresponding to the six stem cell clusters resolved by single-cell RNA sequencing of these libraries were assessed by RNA sequencing and xenografting to monitor inflammation, fibrosis, and mucin secretion. The impact of CFTR activity on these variants after CFTR gene complementation or exposure to CFTR modulators was assessed by molecular and functional studies. Measurements and Main Results: End-stage CF lungs display a stem cell heterogeneity marked by five predominant variants in addition to the normal lung stem cell, of which three are proinflammatory both at the level of gene expression and their ability to drive neutrophilic inflammation in xenografts in immunodeficient mice. The proinflammatory functions of these three variants were unallayed by genetic or pharmacological restoration of CFTR activity. Conclusions: The emergence of three proinflammatory stem cell variants in CF lungs may contribute to the persistence of lung inflammation in patients with CF with advanced disease undergoing CFTR modulator therapy.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Wang S, Niroula S, Hoffman A, et al. Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators. Am J Respir Crit Care Med. 2023. PMID: 37695863. doi:10.1164/rccm.202305-0818OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。